Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6583846 | 0.88 | SCN9A (0.54) | SCN9AROCK1AURKA | |
| SCHEMBL27705134 | 0.88 | RHOA (0.62) | AURKASYK | |
| SCHEMBL30422273 | 0.87 | SCN9A (0.47) | SCN9A | |
| SCHEMBL17630275 | 0.84 | AURKA (0.54) | ROCK1AURKASYK | |
| SCHEMBL6479606 | 0.84 | ABL1 (0.57) | SCN9AROCK1 | |
| SCHEMBL2355018 | 0.84 | SCN9A (0.62) | SCN9A | |
| SCHEMBL14374443 | 0.83 | NFKB1 (0.54) | SYK | |
| SCHEMBL12504952 | 0.81 | ROCK1 (0.55) | SCN9AROCK1AURKASYK | |
| SCHEMBL4726882 | 0.81 | AURKA (0.64) | ROCK1AURKA | |
| SCHEMBL6479037 | 0.81 | AURKA (0.54) | SCN9AAURKASYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2550257-B1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2016-12-21 | — | — | EP | disclosed |
| CN-102933561-B | There is the disubstituted triazine derivatives of pharmaceutical active | Lead Discovery Center Co.,Ltd. (DE) | 2016-05-11 | — | — | CN | disclosed |
| US-20130079345-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-28 | — | — | US | disclosed |
| CN-102933561-A | Pharmaceutically active disubstituted triazine derivatives | LEAD DISCOVERY CENTER GMBH | 2013-02-13 | — | — | CN | disclosed |
| EP-2550257-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | Lead Discovery Center GmbH (DE) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011116951-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079345-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | PDE5A, TESK2, PAK5 | SCN9A 4613/4885ROCK1 375/4885AURKA 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.